AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 1.17
(0.0%)
SEK 1.17
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 38.26 Million SEK | -32.36% |
| 2022 | 56.56 Million SEK | -27.61% |
| 2021 | 78.14 Million SEK | 8.5% |
| 2020 | 72.02 Million SEK | 41.21% |
| 2019 | 51 Million SEK | 41.14% |
| 2018 | 36.13 Million SEK | 235.65% |
| 2017 | 10.76 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 8.78 Million SEK | -12.32% |
| 2024 Q1 | 9.99 Million SEK | 0.69% |
| 2023 Q4 | 9.92 Million SEK | 24.6% |
| 2023 FY | 37.82 Million SEK | -33.13% |
| 2023 Q3 | 7.96 Million SEK | -24.08% |
| 2023 Q2 | 10.49 Million SEK | 7.53% |
| 2023 Q1 | 9.76 Million SEK | -12.5% |
| 2022 FY | 56.56 Million SEK | -27.61% |
| 2022 Q3 | 11.17 Million SEK | -48.22% |
| 2022 Q2 | 21.57 Million SEK | 70.33% |
| 2022 Q1 | 12.66 Million SEK | -44.61% |
| 2022 Q4 | 11.15 Million SEK | -0.13% |
| 2021 Q2 | 15.73 Million SEK | -31.62% |
| 2021 FY | 78.14 Million SEK | 8.5% |
| 2021 Q1 | 23 Million SEK | 26.33% |
| 2021 Q4 | 22.86 Million SEK | 38.23% |
| 2021 Q3 | 16.54 Million SEK | 5.16% |
| 2020 Q1 | 13.85 Million SEK | -12.24% |
| 2020 Q2 | 18.45 Million SEK | 33.26% |
| 2020 FY | 72.02 Million SEK | 41.21% |
| 2020 Q4 | 18.21 Million SEK | -15.31% |
| 2020 Q3 | 21.5 Million SEK | 16.5% |
| 2019 FY | 51 Million SEK | 41.14% |
| 2019 Q4 | 15.78 Million SEK | 17.55% |
| 2019 Q3 | 13.42 Million SEK | 30.26% |
| 2019 Q2 | 10.3 Million SEK | -10.3% |
| 2019 Q1 | 11.49 Million SEK | -12.44% |
| 2018 Q1 | 9.62 Million SEK | 69.8% |
| 2018 FY | 36.13 Million SEK | 235.65% |
| 2018 Q4 | 13.12 Million SEK | 131.45% |
| 2018 Q3 | 5.67 Million SEK | -26.57% |
| 2018 Q2 | 7.72 Million SEK | -19.76% |
| 2017 Q3 | 5 Million SEK | 0.0% |
| 2017 Q4 | 5.66 Million SEK | 13.29% |
| 2017 FY | 10.76 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -188.792% |
| BioGaia AB (publ) | 507.08 Million SEK | 92.455% |
| Enzymatica AB (publ) | 79.92 Million SEK | 52.128% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | -0.094% |
| Gabather AB (publ) | 9.47 Million SEK | -303.863% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -157.068% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | -39.322% |
| Nanexa AB (publ) | 135.78 Million SEK | 71.821% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | -27.07% |
| ODI Pharma AB | -5.00 SEK | 765240100.0% |
| Orexo AB (publ) | 659.4 Million SEK | 94.197% |
| Probi AB (publ) | 208.93 Million SEK | 81.687% |
| Swedencare AB (publ) | 1.12 Billion SEK | 96.607% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 99.593% |
| Toleranzia AB | 6.97 Million SEK | -448.795% |
| Vivesto AB | 355.71 Million SEK | 89.244% |